Current Portfolio CompaniesAIM Health Group Inc.
Lise Watier Cosmétiques Inc.
Schulman Associates IRB
AIM Health Group Inc.
AIM Health Group Inc. (“AIM”) is a fully integrated Canadian healthcare company that provides comprehensive healthcare services and solutions for patients, corporate clients, hospitals and pharmaceutical companies.
In August 2011, Imperial Capital acquired Ontario based AIM Health Group Inc. In business for over 20 years, AIM is recognized for its leadership in pain management, community based infusion services, workplace health, and corporate disability management. AIM’s corporate resume includes several high profile achievements such as: i) operating Canada’s largest community based infusion network; ii) providing workplace health and corporate services to many large corporate and government clients which are serviced through a nation-wide network of consultants; and iii) having a national network of owned and partner medical clinics which provide family, infusion, alternative, and pain management services.
The vision for AIM is to take advantage of the many organic and acquisition based growth opportunities available along its multiple service lines. Furthermore, the Company is well positioned to benefit from favourable trends, including an aging population, de-listing of government funded services, increasing willingness of the Canadian consumer to pay for healthcare services, and the continued importance of healthcare as a key topic among Canadian voters.
A Leading Developer and Marketer of Innovative, High Quality Pet Treat Products
In May 2010, Imperial Capital acquired New Jersey based Petra Pet, Inc., the owner of pet treat brand Beefeaters® and its pet nutrition products affiliate, Petra Vet, LLC. Founded in 1986, the company develops, markets, and distributes branded pet treats including rawhide and porkhide chews, chicken snacks, health supplements, natural treats, dental chews, and hybrids snacks. These products are primarily sold through a wide distribution network of warehouse clubs, grocery stores, pet superstores, and specialty pet retailers throughout the United States, Canada, Mexico, and Europe.
Petra Pet represents a low risk, stable play on some of the most compelling growth drivers in the pet products industry including the increase in pet ownership, the humanization of pets as a member of the family, the heightened awareness of healthy pet eating, the increased spending on pets per capita, and the growing acceptance of new pet products. The company will look to expand through organic and acquisition growth opportunities that help target under-penetrated geographic and market segments, the introduction of new product lines, and enhanced service offerings to existing customers.
Lise Watier Cosmetiques Inc.
A Leading Canadian Cosmetics, Skincare and Fragrance Products Developer and Marketer.
Lise Watier Cosmetiques Inc. (“LWC”), based in Montreal, Quebec, was acquired by Imperial Capital in March 2007. Since 1972, LWC has developed and marketed high-quality, prestige cosmetics. Madame Watier’s original philosophy was that beauty should be accessible to all women and this inspired the development of superior prestige products offered at affordable prices. LWC has expanded nationally and into new product categories, including fragrances and, most recently, skincare products – the fastest growing sector of its business and of the beauty care industry. The compelling value proposition has enabled LWC’s founder, Madame Watier, to create one of the fastest growing cosmetics companies in Canada. LWC’s products have recently been marketed with great success across Canada and internationally (including France, Spain, the Middle East, the Philippines, and Russia). Imperial Capital believes the company has an excellent, well-respected brand that is able to further penetrate the Canadian market, and which can be leveraged into other international markets.
The vision for LWC is to grow the business (i) domestically through the introduction of new products into existing channels of distribution and increasing penetration in markets outside of Québec, (ii) internationally by concentrating on building distribution of the brand in specific high potential markets, and (iii) through strategic acquisitions of companies that can lever off of its existing distribution channels.
Schulman Associates IRB
A U.S. Based Independent Institutional Review Board
Imperial Capital invested in Schulman Associates IRB, Inc. in October 2008. Schulman, based in Cincinnati, Ohio, is one of the largest independent institutional review boards ("IRB") in the United States. Over its 25 year history, the company has grown into an internationally recognized name in the protection of human subjects in clinical trials. It primarily serves the pharmaceutical and medical device industries as a Central IRB on research involving drugs, medical devices and biologics. In that role, Schulman, an accredited IRB, reviews research protocols and consent documents from clinical trials to evaluate compliance with human subject protection regulations.
Schulman's business is a prudent investment because it addresses the growing demand for clinical research testing of new drugs and medical devices, which target the proliferation of chronic diseases and increasing prevalence of diseases associated with an aging population. The vision for Schulman is to grow the business organically throughout North America and to continue to provide the highest level of human subject protection.